Advertisement

A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)

Prithviraj Bose, Lisa Chen, Nichole Cruz, Yongying Jiang, Qi Wu, Philip A Thompson, Shuju Feng, Michael Kroll, Nitin Jain, William G Wierda, Michael J. Keating and Varsha Gandhi

Article Information

Citation 
vol. 130 no. Suppl 1 4307

Print ISSN 
Online ISSN 
History 
  • Published online December 7, 2017.


Contributors 
  • Prithviraj Bose [MD], 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Lisa Chen, 2Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Nichole Cruz [RN], 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Yongying Jiang, 3Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Qi Wu, 4Institute for Applied Cancer Science, UT MD Anderson Cancer Center, Houston, TX
  • Philip A Thompson [MBBS], 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Shuju Feng, 5Department of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Michael Kroll, 5Department of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Nitin Jain [MD], 6Department of Leukemia, MD Anderson Cancer Center, Houston, TX
  • William G Wierda [MD PhD], 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Michael J. Keating [MD], 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Varsha Gandhi [PhD], 2Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output